Niowave and Novartis Enter Global Actinium-225 Supply Agreement to Advance Next-Generation Cancer Therapies
PR Newswire —
Niowave has entered into a new agreement with Novartis to supply Actinium-225, a highly promising medical isotope The long-term supply agreement supports the development of next-generation therapies designed to precisely target and eliminate cancer cells LANSING, Mich., Feb. 11, 2026...